Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NextCure, Inc.NXTC · Entity 7461 | Chief Development Officer | February 28, 2020 | March 03, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NextCure, Inc.
Report date February 28, 2020 · Filed March 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.76 · Expires 2030-02-27 | Direct | 78,200 |
Reported balance
After 2020-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 78,200 · Balance 78,200 F1: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2020 Filed Mar 3, 2020 21:38 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,200 | $0.00 Strike: $41.76 | $0.00 |
DisclosureSEC source: 0001123292-20-000463 · edgar.xml · derivative · entry 1 Bingham James B. · CIK 0001775735 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,200 Underlying: Common Stock · 78,200 shares Expires 2030-02-27 F1 · derivative.exercise_date: One fourth of the option vests on February 28, 2021. The remainder vests in 36 monthly installments beginning on March 28, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.